Posted by Michael Wonder on 31 May 2020
Greater flexibility for Australians with severe asthma with reimbursement of at-home
1 June 2020 - Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of Nucala (mepolizumab)
GSK Australia today announced that a new pre-filled pen (auto-injector) for the self-administration of its targeted therapy for severe eosinophilic asthma patients, Nucala (mepolizumab), will be reimbursed by the Pharmaceutical Benefits Scheme from 1 June 2020.
